Katy Cappell

Kathryn (Katy) Cappell, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Surgery Branch


Dr. Cappell’s research focuses on cellular therapies to treat cancers of the blood including non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, myeloid malignancies, and multiple myeloma. Her research efforts are in the development of phase 1 clinical trials. She is also interested in long-term outcomes following CAR T cell therapy.   

Areas of Expertise

Hematologic Malignancies
Cancer Immunology And Immunotherapy
Cell Therapy
Chimeric Antigen Receptor T Cell Therapy

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.


Selected Key Publications

Long-term outcomes following CAR T cell therapy: what we know so far

Cappell KM and Kochenderfer JN
Nature Reviews Clinical Oncology . 2023. [ Journal Article ]

Long-term follow-up of anti-CD19 chimeric antigen receptor T cell therapy

Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, Rosenberg SA, Kochenderfer JN
Journal of Clinical Oncology . 10:38(32): 3805-3815, 2020. [ Journal Article ]

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

Cappell KM and Kochenderfer JN
Nature Reviews Clinical Oncology . 18(11): 715-727, 2021. [ Journal Article ]

Advance directive utilization is associated with less aggressive end-of-life care in patients undergoing allogeneic hematopoetic cell transplantation

Cappell K, Sundaram V, Park A, Shiraz P, Gupta R, Jenkins P, Periyakoil VSJ, Muffly L
Biol Blood Marrow Transplant . 24(5): 1035-1040 , 2018. [ Journal Article ]